Adding Atezolizumab Improves Survival in Advanced Cervical Cancer

(MedPage Today) -- First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news